Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.

Ghisoni E, Maggiorotto F, Borella F, Mittica G, Genta S, Giannone G, Katsaros D, Sciarrillo A, Ferrero A, Sarotto I, Erriquez J, Di Renzo MF, Aglietta M, Valabrega G.

J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6.

2.

Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

Konda JD, Olivero M, Musiani D, Lamba S, Di Renzo MF.

Mol Oncol. 2017 Jun;11(6):599-611. doi: 10.1002/1878-0261.12042. Epub 2017 May 8.

3.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.

4.

The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs.

Lorenzato A, Torchiaro E, Olivero M, Di Renzo MF.

Eur J Cancer. 2016 Jun;60:59-68. doi: 10.1016/j.ejca.2016.02.022. Epub 2016 Apr 13.

PMID:
27065457
5.

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

Erriquez J, Olivero M, Mittica G, Scalzo MS, Vaira M, De Simone M, Ponzone R, Katsaros D, Aglietta M, Calogero R, Di Renzo MF, Valabrega G.

Oncotarget. 2016 May 3;7(18):26181-91. doi: 10.18632/oncotarget.8325.

6.

Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.

Torchiaro E, Lorenzato A, Olivero M, Valdembri D, Gagliardi PA, Gai M, Erriquez J, Serini G, Di Renzo MF.

Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.

7.

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.

Erriquez J, Becco P, Olivero M, Ponzone R, Maggiorotto F, Ferrero A, Scalzo MS, Canuto EM, Sapino A, Verdun di Cantogno L, Bruna P, Aglietta M, Di Renzo MF, Valabrega G.

Gynecol Oncol. 2015 Sep;138(3):627-33. doi: 10.1016/j.ygyno.2015.06.025. Epub 2015 Jun 20.

PMID:
26100858
8.

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

Olivero M, Dettori D, Arena S, Zecchin D, Lantelme E, Di Renzo MF.

Oncotarget. 2014 Aug 15;5(15):5992-6002.

9.

PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.

Musiani D, Hammond DE, Cirillo L, Erriquez J, Olivero M, Clague MJ, Di Renzo MF.

J Proteome Res. 2014 Nov 7;13(11):4970-82. doi: 10.1021/pr500651n. Epub 2014 Aug 15.

10.

Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.

Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF.

FASEB J. 2014 Sep;28(9):4055-67. doi: 10.1096/fj.13-247924. Epub 2014 Jun 5.

11.

HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.

Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF.

Int J Cancer. 2014 Mar 15;134(6):1289-99. doi: 10.1002/ijc.28464. Epub 2013 Sep 18.

12.

AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.

Lorenzato A, Biolatti M, Delogu G, Capobianco G, Farace C, Dessole S, Cossu A, Tanda F, Madeddu R, Olivero M, Di Renzo MF.

Exp Cell Res. 2013 Oct 15;319(17):2627-36. doi: 10.1016/j.yexcr.2013.07.030. Epub 2013 Aug 13.

PMID:
23948303
13.

Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.

Maniscalco L, Millán Y, Iussich S, Denina M, Sánchez-Céspedes R, Gattino F, Biolatti B, Sasaki N, Nakagawa T, Di Renzo MF, de Las Mulas JM, De Maria R.

BMC Vet Res. 2013 Apr 15;9:80. doi: 10.1186/1746-6148-9-80.

14.

IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.

Pavan S, Olivero M, Corà D, Di Renzo MF.

Eur J Cancer. 2013 Mar;49(4):964-73. doi: 10.1016/j.ejca.2012.09.024. Epub 2012 Oct 15.

PMID:
23079474
15.

Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.

Surbone A, Fuso L, Passera R, Ferrero A, Marchese C, Martino C, Luchin A, Di Renzo MF, Zola P.

BMC Res Notes. 2012 Sep 23;5:517. doi: 10.1186/1756-0500-5-517.

16.

Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.

Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ, Di Renzo MF.

Mol Cell Biol. 2012 Aug;32(15):3081-94. doi: 10.1128/MCB.06160-11. Epub 2012 May 29.

17.

The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C.

Lorenzato A, Martino C, Dani N, Oligschläger Y, Ferrero AM, Biglia N, Calogero R, Olivero M, Di Renzo MF.

FASEB J. 2012 Jun;26(6):2446-56. doi: 10.1096/fj.11-195982. Epub 2012 Mar 2.

PMID:
22389439
18.

The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors.

Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patané S, Calogero R, Ferracini R, Scotlandi K, Fagioli F, Di Renzo MF.

J Bone Miner Res. 2012 Jun;27(6):1322-34. doi: 10.1002/jbmr.1578.

19.

Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2011 May 15;17(10):3146-56. doi: 10.1158/1078-0432.CCR-10-3377. Epub 2011 Mar 29.

20.

Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.

Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell PH, Stamp G, Poulsom R, Pugh CW, Costa B, Bardella C, Di Renzo MF, Kotlikoff MI, Launonen V, Aaltonen L, El-Bahrawy M, Tomlinson I, Pollard PJ.

Cancer Res. 2010 Nov 15;70(22):9153-65. doi: 10.1158/0008-5472.CAN-10-1949. Epub 2010 Oct 26.

21.

Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis.

Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, Cammarata C, Carmeliet P, Olivero M, Di Renzo MF.

FASEB J. 2010 Aug;24(8):2680-8. doi: 10.1096/fj.09-146928. Epub 2010 Mar 30.

PMID:
20354140
22.

met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.

De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Biolatti B, Levine RA, Buracco P, Di Renzo MF.

J Pathol. 2009 Jul;218(3):399-408. doi: 10.1002/path.2549.

23.

ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells.

Cardamone MD, Bardella C, Gutierrez A, Di Croce L, Rosenfeld MG, Di Renzo MF, De Bortoli M.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7420-5. doi: 10.1073/pnas.0903033106. Epub 2009 Apr 21.

24.

A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging.

Miretti S, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, Di Renzo MF, Godio L, Albini A, Buracco P, Ferracini R.

PLoS One. 2008 Mar 19;3(3):e1828. doi: 10.1371/journal.pone.0001828.

25.

A cancer-predisposing "hot spot" mutation of the fumarase gene creates a dominant negative protein.

Lorenzato A, Olivero M, Perro M, Brière JJ, Rustin P, Di Renzo MF.

Int J Cancer. 2008 Feb 15;122(4):947-51.

26.

Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling.

Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K.

Cancer Res. 2007 Aug 15;67(16):7675-85.

27.

The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.

Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF.

Clin Cancer Res. 2007 Apr 1;13(7):2191-8.

28.

A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth.

Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM.

Oncogene. 2007 Feb 15;26(7):1078-87. Epub 2006 Sep 4.

PMID:
16953230
29.

p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis.

Grethe S, Coltella N, Di Renzo MF, Pörn-Ares MI.

Biochem Biophys Res Commun. 2006 Sep 1;347(3):781-90. Epub 2006 Jul 7.

PMID:
16843435
30.

Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin.

Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF.

Mol Cancer Ther. 2006 May;5(5):1126-35.

31.

Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis.

Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A.

Cell Signal. 2006 Nov;18(11):1967-76. Epub 2006 May 3.

PMID:
16677802
32.

MET overexpression turns human primary osteoblasts into osteosarcomas.

Patanè S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF.

Cancer Res. 2006 May 1;66(9):4750-7.

33.

p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.

Coltella N, Rasola A, Nano E, Bardella C, Fassetta M, Filigheddu N, Graziani A, Comoglio PM, Di Renzo MF.

Int J Cancer. 2006 Jun 15;118(12):2981-90.

34.

Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions.

Brière JJ, Favier J, Bénit P, El Ghouzzi V, Lorenzato A, Rabier D, Di Renzo MF, Gimenez-Roqueplo AP, Rustin P.

Hum Mol Genet. 2005 Nov 1;14(21):3263-9. Epub 2005 Sep 29.

PMID:
16195397
35.

Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer.

De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF.

Cancer Res. 2005 Feb 1;65(3):907-12.

36.

Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.

Bardella C, Costa B, Maggiora P, Patane' S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF.

Cancer Res. 2004 Aug 1;64(15):5154-61.

37.

Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin.

Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, Comoglio PM, Di Renzo MF.

Cancer Res. 2004 Mar 1;64(5):1744-50.

38.

Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR.

Ruggiero T, Olivero M, Follenzi A, Naldini L, Calogero R, Di Renzo MF.

Nucleic Acids Res. 2003 Nov 15;31(22):6561-9.

39.

Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.

Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, Ferracini R.

FASEB J. 2003 Jun;17(9):1162-4. Epub 2003 Apr 22.

PMID:
12709413
40.
41.

Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

Lorenzato A, Olivero M, Patanè S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF.

Cancer Res. 2002 Dec 1;62(23):7025-30.

42.

Feline STK gene expression in mammary carcinomas.

De Maria R, Maggiora P, Biolatti B, Prat M, Comoglio PM, Castagnaro M, Di Renzo MF.

Oncogene. 2002 Mar 7;21(11):1785-90.

43.

MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.

Morello S, Olivero M, Aimetti M, Bernardi M, Berrone S, Di Renzo MF, Giordano S.

J Cell Physiol. 2001 Dec;189(3):285-90.

PMID:
11748586
44.

Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases.

Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, Valente G, Comoglio PM, Di Renzo MF.

Int J Cancer. 2000 May 20;89(3):286-92.

45.

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.

Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM.

Oncogene. 2000 Mar 16;19(12):1547-55.

46.

[Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors].

Fracchioli S, Katsaros D, Maggiora P, Di Renzo MF, Massobrio M.

Minerva Ginecol. 1999 Oct;51(10):359-64. Italian.

PMID:
10638160
47.

Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio PM, Di Renzo MF.

Int J Cancer. 1999 Aug 27;82(5):640-3.

48.

Overexpression of the RON gene in human breast carcinoma.

Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM.

Oncogene. 1998 Jun 4;16(22):2927-33.

49.

Control of invasive growth by the HGF receptor family.

Maggiora P, Gambarotta G, Olivero M, Giordano S, Di Renzo MF, Comoglio PM.

J Cell Physiol. 1997 Nov;173(2):183-6. Review. No abstract available.

PMID:
9365519
50.

Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.

Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito GM, Ippolito O, Di Renzo MF, Comoglio P, Fiumara A, Vigneri R.

J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8.

PMID:
9215314

Supplemental Content

Loading ...
Support Center